Overview
- The companies signed a definitive all-stock merger that will combine under the Slate Medicines name and list on Nasdaq under the ticker SLTE.
- Slate secured commitments for a $245 million private placement led by Frazier Life Sciences to provide cash runway and support clinical work on SLTE-1009.
- Under the deal, pre-merger Slate investors and new financing backers are expected to own about 95% of the combined company while Fulcrum shareholders would hold about 5%.
- Fulcrum stopped development of its sickle-cell pill pociredir after the U.S. Food and Drug Administration raised potential cancer risks, and the company cut roughly 85% of its workforce as part of restructuring.
- The merger is targeted to close in the fourth quarter of 2026 and the combined company plans to push SLTE-1009 through Phase I and a Phase II dose-finding study while advancing other pipeline programs such as SLTE-2100.